找回密码
 加入流式中文网

QQ登录

只需一步,快速开始

查看: 1951|回复: 1

Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic …

[复制链接]
发表于 2012-6-6 12:47:20 | 显示全部楼层 |阅读模式

亲爱的FLOWER,加入流式中文网,一起讨论,一起学习,享受更多福利吧!

您需要 登录 才可以下载或查看,没有账号?加入流式中文网

×
这篇文章提示CD58, CD117, or CD14表达水平可能是AML的预后因素之一,可有站友能搞到全文?

http://onlinelibrary.wiley.com/doi/10.1002/cyto.b.20633/pdf
Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia
  • Marianne Hutchings Hoffmann1,
  • Tobias Wirenfeldt Klausen1,
  • Martin Boegsted2,
  • Steffen Falgreen Larsen2,
  • Alexander Schmitz2,
  • Eva Birgitte Leinoe1,
  • Kjeld Schmiegelow3,
  • Henrik Hasle4,
  • Olav Jonas Bergmann1,5,
  • Suzette Sorensen2,
  • Mette Nyegaard2,
  • Karen Dybkær2,
  • Hans Erik Johnsen1,2,*

Article first published online: 10 FEB 2012

Keywords:
  • acute myeloid leukemia;
  • blast;
  • flow cytometry;
  • gene expression;
  • prognosis



Abstract

Background:Individual cellular heterogeneity within the acute myeloid leukemia (AML) bone marrow samples can be observed by multi parametric flow cytometry analysis (MFC) indicating that immunophenotypic screening for leukemic blast subsets may have prognostic impact.

Material and methods:Samples from de novo AML patients of all cytogenetic risk groups were collected at diagnosis and subjected to MFC based on a four-color antibody panels against 33 CD membrane markers and retrospectively analyzed for the leukemia blast expression pattern and mean fluorescence intensity. Identification of the leukemic blast cells was based on right angle light scatter (SSC) and expression of CD45 and the cellular heterogeneity identified by the presence of at least two distinct subsets by any CD marker.

Results:Analysis of marrow samples from 86 patients with cytogenetic intermediate risk identified recurrent heterogeneous blast phenotypes for selected CD markers, three of which had prognostic impact with loss or gain of CD58, CD117, or CD14 expression.
Multivariate Cox regression analysis of diagnostic variables identified poor prognostic factors: Age >55 years, presence of extramedullary disease, WHO performance score >2, a heterogeneous CD58, CD117, or CD14 expression on blast cells. Each variable added to a simple and clinical useful and MFC based prognostic score system associated to inferior survival in the intermediate risk group of AML patients.

Conclusions:These observations support that leukemic blast heterogeneity detected by MFC has additional prognostic significance in de novo AML; however, the score system needs to be prospectively validated in future clinical trials before implementation. © 2012 International Clinical Cytometry Society


组织样本处理不好?流式中文网原研的魔滤®魔杵®套装,低成本解决,高质量收获
发表于 2012-6-12 15:12:48 | 显示全部楼层
我来附上文献全文~~ Clinical Impact of Leukemic Blast Heterogeneity.pdf (1.18 MB, 下载次数: 1)


评分

参与人数 1流星 +2 收起 理由
niwanmao + 2 感谢分享

查看全部评分

组织样本处理不好?流式中文网原研的魔滤®魔杵®套装,低成本解决,高质量收获
您需要登录后才可以回帖 登录 | 加入流式中文网

本版积分规则 需要先绑定手机号

手机版|流式中文网 ( 浙ICP备17054466号-2|浙ICP备17054466号-2 )

浙公网安备 33038202004217号

GMT+8, 2024-5-10 20:55

Powered by Discuz! X3.5

© 2001-2024 Discuz! Team.

快速回复 返回顶部 返回列表